NEWSLETTER

TNA Vaccine Development Services

OPEN CALL: Submit your application now!

TRANSVAC2 offers a wide variety of high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use. These services are not restricted to any disease in particular. Services will be offered free of charge, with few exceptions! Academic and non-academic research groups, SMEs and industries can apply!

Check out TRANSVAC services >>>

Apply here by December 15th, 2020

TRANSVAC & ENOVA Webinar:

Regulatory information for veterinary vaccine development in the EU and where to find it

18th November 2020, at 10:00 AM (CET)

Speaker: Kornelia Grein (www.kgvetmedconsult.com)

Registration: Please email Falko Apel (falko.apel@vformulation.org).

Open Call: Services in focus

Clinical Trial Support

TRANSVAC2 offers services at advanced development stages, like Clinical Trial Support. This service can help you navigate the complicated regulatory landscape by providing necessary information on regulatory and ethical requirements, as well as access to methodological experts for advice and the review of the clinical protocols.
In a study supported by TRANSVAC2, partners at CEA helped elucidate the potential antiviral activity of hydroxychloroquine (HCQ) in vitro and in non-human primates. The study found no antiviral activity nor clinical efficacy of HCQ, regardless of the timing of treatment initiation.

Partners at IRTA and SSI compare four different adjuvants differing in their immunological signatures that may enhance efficacy of conserved epitopes used in universal Flu vaccine.

Metabolomic approaches such as Metabolomics Profiling and Imaging, offer a window into metabolic mechanisms and immunological alterations induced by a vaccine candidate or adjuvant and can even help identify biosignatures of vaccination status or adverse reactions.

The appropriate vector can “make or break” a vaccine candidate. Within, TRANSVAC2, Oxford University offers services to produce Adenovirus and/or MVA vector(s) expressing antigen(s) of interest to the user. This is the same system currently under clinical testing as one of the most advanced SARS-CoV-2 vaccine candidates.

Our services "in action":

CEA
Nature 2020
In a study supported by TRANSVAC2, partners at CEA helped elucidate the potential antiviral activity of hydroxychloroquine (HCQ) in vitro and in non-human primates. The study found no antiviral activity nor clinical efficacy of HCQ, regardless of the timing of treatment initiation.

Check the service related to the paper >>>

IRTA & SSI
Veterinary Research 2020
Partners at IRTA and SSI compare four different adjuvants differing in their immunological signatures that may enhance efficacy of conserved epitopes used in universal Flu vaccine.

Check the service related to the paper >>>

UNISI
Vaccines 2020
TRANSVAC2 Partners at Siena University explore Multiparametric flow cytometry as a particularly suitable tool for deep analysis of immune responses after vaccination.

Check the service related to the paper >>>

Frontiers in Immunology 2019
UNISI partners also optimized a protocol for the detection of multifunctional epitope-specific CD4+ T Cells, which are fundamental in the characterization of immune responses to vaccination.

Check the service related to the paper >>>

TRANSVAC-DS, Towards a sustainable European vaccine infrastructure
Learn about how TRANSVAC-DS consortium is leading the establishment of a sustainable vaccine infrastructure in Europe. Get to know more about the project and partners on the newly launched website.